Cover Image
市場調查報告書

開發藥劑中 CRISPR/Cas 9 遺傳基因編輯趨勢 2016年

CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016'

出版商 HTStec Ltd 商品編碼 353351
出版日期 內容資訊 英文 54 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
開發藥劑中 CRISPR/Cas 9 遺傳基因編輯趨勢 2016年 CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016'
出版日期: 2016年03月02日 內容資訊: 英文 54 Pages
簡介

本報告提供開發藥劑中 CRISPR/Cas 9 遺傳基因編輯相關全球性線上的基準調查結果相關分析。

  • 摘要整理
  • 目錄
  • 調查方法
  • 受訪者的組織與回答
  • 受訪者所屬企業及組織
  • 受訪者的地區
  • 受訪者的工作職位
  • 現在,在藥物研發中實行 CRISPR/Cas 9遺傳基因編輯的受訪者
  • 使用了CRISPR/Cas 9技術的遺傳基因編輯之目前經驗
  • CRISPR/Cas 9遺傳基因編輯技術的使用期間
  • 開發藥劑中CRISPR/Cas 9遺傳基因編輯技術的利用%
  • 受訪者在開發藥劑中利用 CRISPR/Cas 9遺傳基因編輯技術所達成或想達成的效果
  • 致力於CRISPR/Cas 9遺傳基因編輯的FTE數
  • CRISPR/Cas 9遺傳基因編輯最常被應用的藥物研發流程領域
  • 使用CRISPR/Cas 9遺傳基因編輯的主要疾病或研究領域
  • 調查結果摘要(1)
  • 受訪者想採用 CRISPR/Cas 9遺傳基因編輯所達成的效果
  • 在CRISPR/Cas 9遺傳基因編輯上成為目標的基因
  • 開發藥劑中 CRISPR/Cas 9遺傳基因編輯的主要目的
  • 在CRISPR/Cas 9 之前所研究的其他遺傳基因編輯技術
  • CRISPR/Cas 9遺傳基因編輯技術的優點
  • 開發藥劑中 CRISPR/Cas 9遺傳基因編輯最想要的潛在優點 (1)
  • 開發藥劑中 CRISPR/Cas 9遺傳基因編輯最想要的潛在優點 (2)
  • CRISPR/Cas 9遺傳基因編輯技術最具相關性的功能(1)
  • CRISPR/Cas 9遺傳基因編輯技術最具相關性的功能(2)
  • 用於Guide RNA (sgRNA的)設計的生物資訊學工具
  • 將CRISPR/Cas 9 單元傳達到細胞所偏好的手法
  • CRISPR/Cas 9研究上的各種細胞類型的利用
  • 調查結果摘要(2)
  • CRISPR (Guide RNA)程序庫的利用(1)
  • CRISPR (Guide RNA)程序庫的利用(2)
  • CRISPR 程序庫的功能篩檢最大值的細胞試驗指標
  • 各CRISPR/Cas 9遺傳基因編輯計劃數/年度
  • CRISPR/Cas 9遺傳基因編輯試劑的年度預算
  • CRISPR/Cas 9遺傳基因編輯試劑的市場估計
  • CRISPR/Cas 9遺傳基因編輯試劑相關預算的明細
  • CRISPR/Cas 9遺傳基因編輯試劑市場估計的明細
  • 最初想到CRISPR/Cas 9遺傳基因編輯相關試劑的供應商(1)
  • 最初想到CRISPR/Cas 9遺傳基因編輯相關試劑的供應商(2)
  • CRISPR/Cas 9遺傳基因編輯相關試劑的主要供應商(1)
  • CRISPR/Cas 9遺傳基因編輯相關試劑的主要供應商(2)、其他
  • 調查結果摘要(3)
目錄

This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on CRISPR/Cas 9 gene editing in drug discovery carried out in February 2016.

The survey was initiated by HTStec as part of its tracking of emerging life science marketplaces.

The questionnaire was compiled to meet the needs, requirements and interests of the gene editing reagents vendor community. The objective was to comprehensively document the current use of CRISPR (clustered regularly interspaced short palindromic repeats) and the associated nuclease Cas 9 in gene editing in drug discovery applications and to understand its future impact.

Equal emphasis was given to soliciting opinion from all areas and organisations where CRISPR/Cas 9 gene editing is being utilised as part of drug discovery efforts.

The survey looked at the following aspects of CRISPR/Cas 9 gene editing technology as practiced today (2016) and in some cases as predicted for the future (2018): current experience of gene editing; when first started using gene editing; extent utilizing in drug discovery; number of FTE working in respondent's organisation on gene editing; key diseases or research areas using gene editing; what respondents want to achieve with gene editing; genomes being targeted with gene editing; main objectives of gene editing efforts in drug discovery; advantages of CRISPR/Cas 9 gene editing technology; potential benefits of CRISPR/Cas 9 in drug discovery respondents most want to exploit; most relevant features of CRISPR/Cas 9 gene editing technology to respondent's research effort; bioinformatics tools used to design guide RNAs (sgRNAs); how CRISPR/Cas 9 components are delivered into cells; methods used for CRISPR experiments; use of different cell types in CRISPR research; percentage efficiency of gene editing typically achieved; downstream analysis techniques used to validate your CRISPR/Cas 9 gene editing; number of sgRNAs designed per gene targeted; use of multiplexed gene edits; use of CRISPR libraries for target validation or drug mechanism studies and which type of libraries preferred; cellular response endpoints of greatest value in the functional screening of CRISPR libraries; number of different CRISPR/Cas 9 gene editing projects attempted per year; budget for purchasing CRISPR/Cas 9 gene editing related reagents and breakdown into components; supplier/vendor that first comes to mind when thinking of CRISPR/Cas 9 gene editing related reagents; suppliers where respondents currently purchase the majority of their CRISPR/Cas 9 gene editing related reagents; what most limits work on CRISPR/Cas 9 gene editing today; and any unmet needs that exist in CRISPR/Cas 9 gene editing related to drug discovery today.

The main questionnaire consisted of 29 multi-choice questions and 2 open-ended question. In addition, there were 6 questions related solely to survey demographics.

The survey collected 96 validated responses, of these 79% provided comprehensive input.

Survey responses were geographically split: 47% Europe; 27% North America; 21% Asia (excluding Japan & China); 2% China; 2% Rest of World; and 1% Japan.

Survey respondents were drawn from persons or groups interested in the gene editing, and undertaking or planning future investigation of CRISPR/Cas 9 in drug discovery related applications.

Respondents came from 59 University/Research Inst./Gov't Lab/Not-For-Profit Facilities; 10 Biotech Companies; 8 Large Pharma; 8 Medical School/Hospital/Clinics; 5 Medium-Small Pharma; 3 Contract Research Organisations; and 3 Agrochemical/Agri-Biotech Companies.

Most survey respondents had a senior job role or position which was in descending order: 22 principal investigators; 16 senior scientists/researchers; 12 post-docs; 10 professors/assistant professors; 9 research scientists/associates; 7 department heads; 6 section/group leaders; 5 directors; 5 graduate students; 1 research technician; 1 lab manager; 1 vice president; and 1 other.

Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was fully reanalyzed after sub-division into the following 5 survey groups: 1) Experienced User; 2) Limited Experience; 3) Applying To Drug Discovery Process; 4) Industry; and 5) University Research. The full report gives details of how these survey groups were segmented.

<50% of respondents were currently undertaking CRISPR/Cas9 gene editing related to drug discovery applications, the remainder were not yet fully undertaking, but planned future investigation.

Most respondents current experience of gene editing with CRISPR/Cas 9 technology and its potential in drug discovery was low i.e. have made some initial investigations.

The median time period since respondents had first started using or investigating CRISPR/Cas 9 gene editing technology was 6-12 months ago.

The median % use of CRISPR/Cas 9 gene editing technology in drug discovery was minimal use (<25% of research effort) today (2016).

The median number of scientists working full time (FTEs) on CRISPR/Cas 9 gene editing in respondent's organisation today (2016) was 2 FTEs.

Most respondents were applying or intending to apply CRISPR/Cas 9 gene editing to basic drug research.

Oncology/cancer was the key disease or research area most targeted by CRISPR/Cas 9 gene editing.

The majority want to achieve a gene knockout using CRISPR/Cas 9 gene editing technology.

The majority were targeting their CRISPR/Cas 9 gene editing research against the human genome.

Identification of new therapeutic targets was the main objective of CRISPR/Cas 9 gene editing in drug discovery.

Most respondents had not investigated other gene editing technologies prior to CRISPR/Cas 9 availability.

Efficiency (i.e. edit targets sequences at surprisingly high rates) was ranked the main advantage of CRISPR/Cas 9 gene editing technology.

Complete genetic knockout, while minimising off-target effects was rated the potential benefit of CRISPR/Cas 9 in drug discovery most respondents were interested in exploiting.

Allows for efficient introduction of engineered alterations into the genome was rated the most relevant features of CRISPR/Cas 9 technology to respondent's research.

The bioinformatics tools most used to design sgRNAs were software supplied by vendors.

The preferred method of delivery of CRISPR/Cas 9 components into the cell was standard chemical (lipid-mediated) transfection.

Gene knockout by non-homologous end joining (NHEJ) was the technology most used for CRISPR/Cas 9 experiments.

The cell type most used today (2016) in CRISPR/Cas 9 research was tumor cell lines.

A median of 26-50% efficiency of gene editing was typically achieved in CRISPR experiments.

The downstream analytical technique most used to validate CRISPR/Cas 9 gene edits was PCR.

The median number of guide RNAs (sgRNAs) designed per gene target edited was 2 sgRNAs.

The majority were not undertaking multiplexing - but plan future investigation to deliver sgRNAs targeting multiple genes to multiplex CRISPR/Cas 9 gene edits.

The majority plan to use CRISPR (guide RNA) libraries for target validation or drug mechanism studies, and prefer to use arrayed CRISPR libraries.

A reporter assay was ranked the cellular response endpoints (outputs) of greatest value in the functional screening of CRISPR (guide RNA) libraries.

A median of 2-3 CRISPR/Cas 9 gene editing projects were attempted per year today (2016).

The median annual budget for CRISPR/Cas 9 gene editing related reagents was $2.5K-$5K per lab per year today (2016).

A bottom-up model was developed to estimate the market for CRISPR/Cas 9 gene editing related reagents using respondent data on their budgets derived from this survey. The CRISPR/Cas 9 gene editing related reagents market (used specifically for drug discovery applications, as distinct from all other research applications) was estimated to be around $30M today (2016). CAGR estimates and segmentation are given in the full report.

The main components of the CRISPR/Cas 9 gene editing related reagents budget were individually purchased CRISPR/Cas9 reagents and transfection reagents.

The supplier/vendor of CRISPR/Cas 9 gene editing related reagents that first comes into the mind of survey respondents was AddGene.

The main suppliers from which respondents currently purchase the majority of their CRISPR/Cas 9 gene editing related reagents were AddGene, Millipore Sigma and Thermo Scientific.

Delivery of CRISPR components into the target cell or organism was ranked what most limits work on CRISPR/Cas 9 gene editing today.

All Respondents feedback on any unmet needs that exist today in CRISPR/Cas 9 gene editing related to drug discovery were documented.

The full report provides the data, details of the breakdown of the responses for each question, its segmentation and the estimates for the future (2018). It also highlights some interesting differences between survey groups.

Table of Contents

  • Executive Summary
  • Table Of Contents
  • Survey Methodology
  • Organisation & Response Of Survey Participants
  • Respondent's Company Or Organisational Origin
  • Respondent's Geographic Origin
  • Respondent's Job Role
  • Respondents Currently Undertaking CRISPR/Cas9 Gene Editing In DD
  • Current Experience Of Gene Editing With CRISPR/Cas 9 Technology
  • Time Period Of Use Of CRISPR/Cas 9 Gene Editing Technology
  • % Use Of CRISPR/Cas 9 Gene Editing Technology In Drug Discovery
  • What Respondents Have Achieved Or Want To Achieve From Using CRISPR/Cas 9 Gene Editing Technology In Drug Discovery
  • Number Of FTEs Working On CRISPR/Cas 9 Gene Editing
  • Area In Drug Discovery Process Where Most Applying CRISPR/Cas 9 Gene Editing
  • Key Diseases Or Research Area Using CRISPR/Cas 9 Gene Editing
  • Summary Of Survey Findings (1)
  • What Respondents Want To Achieve Using CRISPR/Cas 9 Gene Editing
  • Genomes Being Targeted With CRISPR/Cas 9 Gene Editing
  • Main Objectives Of CRISPR/Cas 9 Gene Editing In Drug Discovery
  • Other Gene Editing Technologies Investigated Prior To CRISPR/Cas 9
  • The Advantages Of CRISPR/Cas 9 Gene Editing Technology
  • Most Wanted Potential Benefits Of CRISPR/Cas 9 In Drug Discovery (1)
  • Most Wanted Potential Benefits Of CRISPR/Cas 9 In Drug Discovery (2)
  • Most Relevant Features Of CRISPR/Cas 9 Gene Editing Technology (1)
  • Most Relevant Features Of CRISPR/Cas 9 Gene Editing Technology (2)
  • Bioinformatics Tools Used To Design Guide RNAs (sgRNA)
  • Preferred Method Of Delivery Of CRISPR/Cas 9 Components Into Cells
  • Methodology Most Used For CRISPR/Cas 9 Experiments
  • Use Of Different Cell Types In CRISPR/Cas 9 Research
  • Efficiency Of Gene Editing Typically Achieved In CRISPR Experiments
  • Downstream Analytical Techniques Used To Validate CRISPR/Cas 9 Gene Editing
  • Number Of Guide RNAs Designed Per Target Gene Edited
  • Multiplexing CRISPR/Cas 9 Gene Edits
  • Summary Of Survey Findings (2)
  • Use Of CRISPR (Guide RNA) Libraries (1).
  • Use Of CRISPR (Guide RNA) Libraries (2).
  • Cellular Endpoints Of Greatest Value In The Functional Screening Of CRISPR Libraries
  • Number Of Different CRISPR/Cas 9 Gene Editing Projects Attempted Per Year
  • Annual Budgets For CRISPR/Cas 9 Gene Editing Related Reagents
  • Market Estimate For CRISPR/Cas 9 Gene Editing Related Reagents
  • Breakdown Of CRISPR/Cas 9 Gene Editing Related Reagents Budget
  • Breakdown Of CRISPR/Cas 9 Gene Editing Related Reagents Market Estimate
  • Supplier Of CRISPR/Cas9 Gene Editing Related Reagents That First Comes To Mind (1)
  • Supplier Of CRISPR/Cas9 Gene Editing Related Reagents That First Comes To Mind (2)
  • Main Suppliers Of CRISPR/Cas9 Gene Editing Related Reagents (1)
  • Main Suppliers Of CRISPR/Cas9 Gene Editing Related Reagents (2)
  • What Most Limits Work On CRISPR/Cas 9 Gene Editing Today
  • Unmet Needs In CRISPR/Cas 9 Gene Editing Related To Drug Discovery Today
  • Summary Of Survey Findings (3)
Back to Top